

REMARKS

Claim 1, 16-18, and 31 have been amended in this response. Claims 32 and 33 have been added. Claims 11-15, 19 and 20 have been cancelled herein. Claims 1-10, 16-18, 21-24, 31-33 are currently pending. Favorable consideration of the claims is requested in light of the amendments and comments provided herein.

Of the claims still under consideration, Claim 1-10, 21-24, and 31 currently stand as rejected under 35 USC 102(b) as anticipated by US3949939 to BROWN. Further, Claims 16-17 stand rejected as obvious over Brown in view the knowledge of one of ordinary skill.

Reconsideration, withdrawal of the present rejections, and allowance of the claims is requested In light of the amendments made herein. BROWN clearly does not disclose a nasal dispensing nozzle having the channel wall and insert requirements of amended claim 1. Moreover, such requirements of the claimed nozzle would not be obviously derivable from BROWN. To find otherwise could only be based on hindsight of the claimed nozzle.

As such, the pending claims define novel and inventive subject matter having regard to BROWN.

Should any outstanding issues remain, the Examiner is encouraged to contact Applicant's undersigned representative.

Application No. 10/553,668
Attorney Docket No. PB60094USW

Respectfully submitted:

/James P. Riek/

James P. Riek
Attorney for Applicants
Reg. No. 39,009

29 August 2008

Date: _____
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-1891
Fax: (919) 483-7988